Vascular Technology, Inc.

interest in vulnerable plaque is erupting. Device companies have taken the lead, but as biologic solution emerge, will that lead last? The second of a two-part series. by David Cassak As we noted last

Better understanding and detection of plaque may lead to new treatments for symptomless heart disease patients at risk. by Mary Stuart Heart disease, "the silent killer," is even more silent than we t

A venture-backed Canadian biotechnology industry is in its infancy, but faced with hostile capital markets, start-ups need clear exit plans. Consolidation's already started. by Mary Stuart It is perha

Each year, approximately one million people in the US will suffer from acute myocardial infarction (AMI), or heart attack, caused by diseases of the circulatory system. Of these victims, 40% will have